Related references
Note: Only part of the references are listed.Exclusive Chemoradiotherapy With or Without Radiation Dose Escalation in Esophageal Cancer: Multicenter Phase 2/3 Randomized Trial CONCORDE (PRODIGE-26)
G. Crehange et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2021)
Involved-Field Irradiation in Definitive Chemoradiotherapy for Locoregional Esophageal Squamous Cell Carcinoma: Results From the ESO-Shanghai 1 Trial
Hongcheng Zhu et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2021)
KEYNOTE-975 study design: a Phase III study of definitive chemoradiotherapy plus pembrolizumab in patients with esophageal carcinoma
Manish A. Shah et al.
FUTURE ONCOLOGY (2021)
Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer
Ronan J. Kelly et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
RATIONALE 311: tislelizumab plus concurrent chemoradiotherapy for localized esophageal squamous cell carcinoma
Rong Yu et al.
FUTURE ONCOLOGY (2021)
Randomized Phase II Study of PET Response-Adapted Combined Modality Therapy for Esophageal Cancer: Mature Results of the CALGB 80803 (Alliance) Trial
Karyn A. Goodman et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Randomized Study on Dose Escalation in Definitive Chemoradiation for Patients With Locally Advanced Esophageal Cancer (ARTDECO Study)
Maarten C. C. M. Hulshof et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Pan-cancer prediction of radiotherapy benefit using genomic-adjusted radiation dose (GARD): a cohort-based pooled analysis
Jacob G. Scott et al.
LANCET ONCOLOGY (2021)
Preoperative cisplatin, fluorouracil, and docetaxel with or without radiotherapy after poor early response to cisplatin and fluorouracil for resectable oesophageal adenocarcinoma (AGITG DOCTOR): results from a multicentre, randomised controlled phase II trial
A. P. Barbour et al.
ANNALS OF ONCOLOGY (2020)
High vs. Low Radiation Dose of Concurrent Chemoradiotherapy for Esophageal Carcinoma With Modern Radiotherapy Techniques: A Meta-Analysis
Xin Sun et al.
FRONTIERS IN ONCOLOGY (2020)
The global, regional, and national burden of oesophageal cancer and its attributable risk factors in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017
Farin Kamangar et al.
LANCET GASTROENTEROLOGY & HEPATOLOGY (2020)
Comparing Paclitaxel Plus Fluorouracil Versus Cisplatin Plus Fluorouracil in Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Cancer: A Randomized, Multicenter, Phase III Clinical Trial
Yun Chen et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Driving developments in UK oesophageal radiotherapy through the SCOPE trials
S. Gwynne et al.
RADIATION ONCOLOGY (2019)
PET-directed combined modality therapy for gastroesophageal junction cancer: First results of the prospective MEMORI trial.
Sylvie Lorenzen et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Results of a Phase 1/2 Trial of Chemoradiotherapy With Simultaneous Integrated Boost of Radiotherapy Dose in Unresectable Locally Advanced Esophageal Cancer
Dawei Chen et al.
JAMA ONCOLOGY (2019)
Effect of modern high-dose versus standard-dose radiation in definitive concurrent chemo-radiotherapy on outcome of esophageal squamous cell cancer: a meta-analysis
He-San Luo et al.
RADIATION ONCOLOGY (2019)
Epidemiology of Esophageal Squamous Cell Carcinoma
Christian C. Abnet et al.
GASTROENTEROLOGY (2018)
Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries
Claudia Allemani et al.
LANCET (2018)
Detection of residual disease after neoadjuvant chemoradiotherapy for oesophageal cancer (preSANO): a prospective multicentre, diagnostic cohort study
Bo Jan Noordman et al.
LANCET ONCOLOGY (2018)
Dose escalation intensity-modulated radiotherapy-based concurrent chemoradiotherapy is effective for advanced-stage thoracic esophageal squamous cell carcinoma
Chia-Lun Chang et al.
RADIOTHERAPY AND ONCOLOGY (2017)
Effect of the Addition of Cetuximab to Paclitaxel, Cisplatin, and Radiation Therapy for Patients With Esophageal Cancer The NRG Oncology RTOG 0436 Phase 3 Randomized Clinical Trial
Mohan Suntharalingam et al.
JAMA ONCOLOGY (2017)
Radiation Dose Escalation in Esophageal Cancer Revisited: A Contemporary Analysis of the National Cancer Data Base, 2004 to 2012
Jeffrey V. Brower et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2016)
Gross tumor volume is the prognostic factor for squamous cell esophageal cancer patients treated with definitive radiotherapy
Yun Chen et al.
JOURNAL OF THORACIC DISEASE (2016)
Safety of dose escalation by simultaneous integrated boosting radiation dose within the primary tumor guided by 18FDG-PET/CT for esophageal cancer
Wen Yu et al.
RADIOTHERAPY AND ONCOLOGY (2015)
Radiobiological Determination of Dose Escalation and Normal Tissue Toxicity in Definitive Chemoradiation Therapy for Esophageal Cancer
Samantha Warren et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2014)
Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5/ACCORD17): final results of a randomised, phase 2/3 trial
Thierry Conroy et al.
LANCET ONCOLOGY (2014)
Evaluation of early response to concomitant chemoradiotherapy by interim 18F-FDG PET/CT imaging in patients with locally advanced oesophageal carcinomas
Xavier Cuenca et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2013)
Chemoradiotherapy with or without cetuximab in patients with oesophageal cancer (SCOPE1): a multicentre, phase 2/3 randomised trial
Thomas Crosby et al.
LANCET ONCOLOGY (2013)
Failure patterns in patients with esophageal cancer treated with definitive chemoradiation
James Welsh et al.
CANCER (2012)
Addition of bevacizumab to standard chemoradiation for locoregionally advanced nasopharyngeal carcinoma (RTOG 0615): a phase 2 multi-institutional trial
Nancy Y. Lee et al.
LANCET ONCOLOGY (2012)
18F-FDG PET-Guided Salvage Neoadjuvant Radiochemotherapy of Adenocarcinoma of the Esophagogastric Junction: The MUNICON II Trial
Christian Meyer Zum Bueschenfelde et al.
JOURNAL OF NUCLEAR MEDICINE (2011)
Outcomes of Patients With Esophageal Cancer Staged With [18F] Fluorodeoxyglucose Positron Emission Tomography (FDG-PET): Can Postchemoradiotherapy FDG-PET Predict the Utility of Resection?
Arta Monir Monjazeb et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
STUDY TO DETERMINE ADEQUATE MARGINS IN RADIOTHERAPY PLANNING FOR ESOPHAGEAL CARCINOMA BY DETAILING PATTERNS OF RECURRENCE AFTER DEFINITIVE CHEMORADIOTHERAPY
Michael R. Button et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2009)
PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction:: The MUNICON phase II trial
Florian Lordick et al.
LANCET ONCOLOGY (2007)
Clinical and psychometric validation of an EORTC questionnaire module, the EORTC QLQ-OES18, to assess quality of life in patients with oesophageal cancer
JM Blazeby et al.
EUROPEAN JOURNAL OF CANCER (2003)
Share Paper
